Dr Iman El-Hariry, VP, Clinical Research, Synta Pharmaceuticals, United States will be presenting on the above subject at Drug Discovery World Asia 2012, part of a series of conferences at 5th Annual BioPharma Asia Convention 2012.
Dr Iman is a clinical Oncologist, earned her MD in Alexandria medical school in Egypt, and her PhD at the Imperial college, London, UK. She moved to the Pharmaceutical sector in 1998 and worked as a leader of oncology in GSK for 10 years, based in UK where she lead the clinical development of lapatinib, a dual tyrosine kinase inhibitor of HER2 and EGFR. In 2009, she moved to Astellas, USA, where she assumed the role of Global Head of Oncology for one year. In 2010 Iman moved to Boston where she currently holds the role of VP Clinical Research at Synta Pharmaceuticals. Iman has developed a solid experience in oncology drug development from phase 0 to Phase IV, with extensive experience in the US, Europe and the Middle East in Health Services and the Pharmaceutical sector. Iman has considerable experience in strategic planning, and leading and implementing significant clinical projects with novel drug candidates. She has authored several publications in peer reviewed journals presented in multiple national and international conferences
Dr Iman will be speaking about the following topics:
1. Combining innovative biomarkers with mutation assays and digital pathology to develop modern personalized medicine
2. Pioneering next generation of treatments through biomarkers and related advanced technologies to accelerate future of cancer research
3. Refining biomarker capabilities through combining therapies: Targeted therapeutic cocktails and typical course of chemotherapeutic- for cost and time effectiveness